Galectin-3 Binding Protein in Cardiovascular Disease and Chronic Heart Failure
Launched by HEIDELBERG UNIVERSITY · Sep 27, 2010
Trial Information
Current as of May 27, 2025
Completed
Keywords
ClinConnect Summary
Chronic heart failure represents an important cause of disease burden in Western countries. Heart failure can be either caused by vascular disease (i.e. cardiomypathy (CMP) due to coronary artery disease ("ischemic/ICMP")) or by myocardial conditions (i.e. dilated cardiomyopathies (DCMP) resulting from other causes like familial disposition, drug toxicity, etc.). Gold standard for the diagnosis of CMPs is the coronary angiography in conjunction with left ventricular angiography and myocardial biopsy, non-invasive markers include C-reactive protein (CRP) for ICMP and brain natriuretic protei...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • impaired ventricular function
- Exclusion Criteria:
- • neoplastic disease
- • infections with hepatitis C or HIV
About Heidelberg University
Heidelberg University, a prestigious institution located in Germany, is renowned for its commitment to advancing medical research and clinical innovation. With a strong emphasis on interdisciplinary collaboration, the university fosters a dynamic environment for conducting clinical trials that aim to enhance patient care and improve health outcomes. Leveraging cutting-edge technology and a robust network of healthcare professionals, Heidelberg University is dedicated to exploring novel therapeutic approaches and contributing to the global medical community through rigorous scientific inquiry and ethical research practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Heidelberg, , Germany
Patients applied
Trial Officials
Christian A Gleissner, MD
Principal Investigator
Heidelberg University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials